{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:28:27Z","timestamp":1789118907279,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12688-9","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:03:22Z","timestamp":1789117402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dysregulation of the TLR4\/MYD88 Signaling Pathway in Egyptian Females with Breast Cancer: Implications for Tumor Progression"],"prefix":"10.1007","volume":"53","author":[{"given":"Sulaiman Mohammed","family":"Alshaban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawfik","family":"Elkhadrary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Elnahhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Awadalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omali Y.","family":"El-Khawaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"12688_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"12688_CR2","unstructured":"WHO (2021) Breast cancer. [cited 2022 10 January 2022]; Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"12688_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, Huang L, Liu CC, Shao ZM, Yu KD (2025) Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther 10:49. https:\/\/doi.org\/10.1038\/s41392-024-02108-4","journal-title":"Signal Transduct Target Ther"},{"key":"12688_CR4","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S2214-109X(23)00365-7","volume":"11","author":"C Frick","year":"2023","unstructured":"Frick C, Rumgay H, Vignat J, Ginsburg O, Nolte E, Bray F, Soerjomataram I (2023) Quantitative estimates of preventable and treatable deaths from 36 cancers worldwide: a population-based study. Lancet Global Health 11:1700\u20131712. https:\/\/doi.org\/10.1016\/S2214-109X(23)00365-7","journal-title":"Lancet Global Health"},{"key":"12688_CR5","unstructured":"WHO (2020) Cancer Country Profile 2020: Egypt. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-NMH-NVI-2020.1."},{"key":"12688_CR6","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S0140-6736(23)02802-7","volume":"403","author":"M Hickey","year":"2024","unstructured":"Hickey M, Basu P, Sassarini J, Stegmann ME, Weiderpass E, Chilowa KN, Yip CH, Partridge AH, Brennan DJ (2024) Managing menopause after cancer. Lancet 403:984\u2013996. https:\/\/doi.org\/10.1016\/S0140-6736(23)02802-7","journal-title":"Lancet"},{"key":"12688_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41523-022-00443-9","volume":"8","author":"A Kostecka","year":"2022","unstructured":"Kostecka A, Nowikiewicz T, Olszewski P, Koczkowska M, Horbacz M, Heinzl M, Andreou M, Salazar R, Mair T, Madanecki P, Gucwa M, Davies H, Skokowski J, Buckley PG, Peksa R, Srutek E, Szylberg L, Hartman J, Jankowski M, Zegarski W, Tiemann-Boege I, Dumanski JP, Piotrowski A (2022) High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing. NPJ Breast Cancer 8:76. https:\/\/doi.org\/10.1038\/s41523-022-00443-9","journal-title":"NPJ Breast Cancer"},{"key":"12688_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13053-025-00313-y","volume":"23","author":"R Dwornik","year":"2025","unstructured":"Dwornik R, Bia\u0142kowska K (2025) Insights into genetic modifiers of breast cancer risk in carriers of BRCA1 and BRCA2 pathogenic variants. Heredit Cancer Clin Practice 23:15","journal-title":"Heredit Cancer Clin Practice"},{"key":"12688_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1051\/medsci\/200723167","volume":"23","author":"Y Delneste","year":"2007","unstructured":"Delneste Y, Beauvillain C, Jeannin P (2007) Innate immunity: structure and function of TLRs. Med Sci (Paris) 23:67\u201373. https:\/\/doi.org\/10.1051\/medsci\/200723167","journal-title":"Med Sci (Paris)"},{"key":"12688_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:373\u2013384. https:\/\/doi.org\/10.1038\/ni.1863","journal-title":"Nat Immunol"},{"key":"12688_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01188","volume":"9","author":"T Ou","year":"2018","unstructured":"Ou T, Lilly M, Jiang W (2018) The pathologic role of Toll-like receptor 4 in prostate cancer. Front Immunol 9:1188. https:\/\/doi.org\/10.3389\/fimmu.2018.01188","journal-title":"Front Immunol"},{"key":"12688_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00262-020-02508-9","volume":"69","author":"K Yahiro","year":"2020","unstructured":"Yahiro K, Matsumoto Y, Yamada H, Endo M, Setsu N, Fujiwara T, Nakagawa M, Kimura A, Shimada E, Okada S, Oda Y, Nakashima Y (2020) Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8-positive cytotoxic lymphocytes. Cancer Immunol Immunother 69:745\u2013758. https:\/\/doi.org\/10.1007\/s00262-020-02508-9","journal-title":"Cancer Immunol Immunother"},{"key":"12688_CR13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.74636","volume":"11","author":"CD Barbosa","year":"2022","unstructured":"Barbosa CD, Canto FB, Gomes A, Brandao LM, Lima JR, Melo GA, Granato A, Neves EGA, Dutra WO, Oliveira AC, Nobrega A, Bellio M (2022) Cytotoxic CD4(+) T cells driven by T-cell intrinsic IL-18R\/MyD88 signaling predominantly infiltrate Trypanosoma cruzi-infected hearts. Elife 11:e74636. https:\/\/doi.org\/10.7554\/eLife.74636","journal-title":"Elife"},{"key":"12688_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/biom14050562","volume":"14","author":"J Song","year":"2024","unstructured":"Song J, Li Y, Wu K, Hu Y, Fang L (2024) MyD88 and its inhibitors in cancer: prospects and challenges. Biomolecules 14:562. https:\/\/doi.org\/10.3390\/biom14050562","journal-title":"Biomolecules"},{"key":"12688_CR15","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Th\u00fcrlimann B, Senn H-J (2011) Strategies for subtypes\u2014dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736\u20131747","journal-title":"Ann Oncol"},{"key":"12688_CR16","doi-asserted-by":"publisher","unstructured":"Goldhirsc A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ, Panel M (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24:2206-23. https:\/\/doi.org\/10.1093\/annonc\/mdt303","DOI":"10.1093\/annonc\/mdt303"},{"key":"12688_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.971288","volume":"12","author":"C Thakur","year":"2022","unstructured":"Thakur C, Qiu Y, Fu Y, Bi Z, Zhang W, Ji H, Chen F (2022) Epigenetics and environment in breast cancer: new paradigms for anti-cancer therapies. Front Oncol 12:971288. https:\/\/doi.org\/10.3389\/fonc.2022.971288","journal-title":"Front Oncol"},{"key":"12688_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.33393\/jcb.2022.2446","volume":"11","author":"D Hasan","year":"2022","unstructured":"Hasan D (2022) Diagnostic impact of CEA and CA 15\u20133 on chemotherapy monitoring of breast cancer patients. J Circ Biomark 11:57\u201363","journal-title":"J Circ Biomark"},{"key":"12688_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.22141\/2224-0721.22.1.2026.1670","volume":"22","author":"MM Al Alouci","year":"2026","unstructured":"Al Alouci MM, Mohammed FM, Qassam ZM, Mohsein OA (2026) Serum biomarkers (CA 15-3, CEA) and hormonal receptor status as predictors of breast cancer recurrence. Int J Endocrinol (Ukraine) 22:21\u201327","journal-title":"Int J Endocrinol (Ukraine)"},{"key":"12688_CR20","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21543","volume":"8","author":"L Ding","year":"2017","unstructured":"Ding L, Jiang Q, Li G, Shen J, Du J, Lu X, Xiong X (2017) Comprehensive assessment of association between TLR4 gene polymorphisms and cancer risk: a systematic meta-analysis. Oncotarget 8:100593","journal-title":"Oncotarget"},{"key":"12688_CR21","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/1535-7163.MCT-12-1019","volume":"12","author":"S Rajput","year":"2013","unstructured":"Rajput S, Volk-Draper LD, Ran S (2013) TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther 12:1676\u20131687","journal-title":"Mol Cancer Ther"},{"key":"12688_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2025.103009","author":"KP,R Zaragoza","year":"2025","unstructured":"Zaragoza KP R, Castillo-Sanchez M, Sanchez-Juarez P, Cortes-Reynosa P, Salazar EP (2025) Linoleic acid induces migration and invasion through TLR4 in breast cancer cells. Tissue Cell. https:\/\/doi.org\/10.1016\/j.tice.2025.103009","journal-title":"Tissue Cell"},{"key":"12688_CR23","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.3892\/mmr.2018.9326","volume":"18","author":"K Wu","year":"2018","unstructured":"Wu K, Zhang H, Fu Y, Zhu Y, Kong L, Chen L, Zhao F, Yu L, Chen X (2018) TLR4\/MyD88 signaling determines the metastatic potential of breast cancer cells. Mol Med Rep 18:3411\u20133420. https:\/\/doi.org\/10.3892\/mmr.2018.9326","journal-title":"Mol Med Rep"},{"key":"12688_CR24","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/ar.23590","volume":"300","author":"J Li","year":"2017","unstructured":"Li J, Yin J, Shen W, Gao R, Liu Y, Chen Y, Li X, Liu C, Xiang R, Luo N (2017) TLR4 promotes breast cancer metastasis via Akt\/GSK3\u03b2\/\u03b2-catenin pathway upon LPS stimulation. Anat Rec 300:1219\u20131229","journal-title":"Anat Rec"},{"key":"12688_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.598939","volume":"11","author":"F Long","year":"2020","unstructured":"Long F, Lin H, Zhang X, Zhang J, Xiao H, Wang T (2020) Atractylenolide-I suppresses tumorigenesis of breast cancer by inhibiting toll-like receptor 4-mediated nuclear factor-\u03bab signaling pathway. Front Pharmacol 11:598939","journal-title":"Front Pharmacol"},{"key":"12688_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-29-92","volume":"29","author":"H Yang","year":"2010","unstructured":"Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, Shen H, Zhu X (2010) Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res 29:92. https:\/\/doi.org\/10.1186\/1756-9966-29-92","journal-title":"J Exp Clin Cancer Res"},{"key":"12688_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111639","volume":"9","author":"FJ Ma","year":"2014","unstructured":"Ma FJ, Liu ZB, Hu X, Ling H, Li S, Wu J, Shao ZM (2014) Prognostic value of myeloid differentiation primary response 88 and Toll-like receptor 4 in breast cancer patients. PLoS ONE 9:e111639. https:\/\/doi.org\/10.1371\/journal.pone.0111639","journal-title":"PLoS ONE"},{"key":"12688_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4066\/biomedicalresearch.29-17-2928","volume":"29","author":"L Zhou","year":"2018","unstructured":"Zhou L, Liang H-Z, Zhang H, Wang X-Y, Xu D, Wu J (2018) Significance of TLR4, MyD88 and STAT3 expression in colorectal cancer. Biomed Res 29:317\u2013322","journal-title":"Biomed Res"},{"key":"12688_CR29","first-page":"475","volume":"42","author":"L Xu-Yang","year":"2021","unstructured":"Xu-Yang L, Ping X, Sheng-xiang L, Zhi-Mei Z, Lu W, Shu-Xian Z, Yan-qin M (2021) Expression and clinical signficance of TLR4 and MyD88 in esophageal squamous cell carcinoma. J Sun Yat-Sen Univ Med Sci 42:475\u2013481","journal-title":"J Sun Yat-Sen Univ Med Sci"},{"key":"12688_CR30","first-page":"786","volume":"21","author":"S Shi","year":"2020","unstructured":"Shi S, Xu C, Fang X, Zhang Y, Li H, Wen W, Yang G (2020) Expression profile of Toll-like receptors in human breast cancer. Mol Med Rep 21:786\u2013794","journal-title":"Mol Med Rep"},{"key":"12688_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2024.118000","volume":"116","author":"D Kathirasan","year":"2024","unstructured":"Kathirasan D, Normizan SB, Salleh N, Poh-Yen K (2024) Recent progress on small molecule TLR4 antagonist against triple-negative breast cancer progression and complications. Bioorg Med Chem 116:118000. https:\/\/doi.org\/10.1016\/j.bmc.2024.118000","journal-title":"Bioorg Med Chem"},{"key":"12688_CR32","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4751260","author":"J Chen","year":"2017","unstructured":"Chen J, Zhang L, Shu Y, Chen L, Zhu M, Yao S, Wang J, Wu J, Liang G, Wu H (2017) Curcumin analogue CA15 exhibits anticancer effects on HEp\u20102 cells via targeting NF\u2010\u03baB. BioMed Res Int. https:\/\/doi.org\/10.1155\/2017\/4751260","journal-title":"BioMed Res Int"},{"key":"12688_CR33","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","volume":"180","author":"KA Fitzgerald","year":"2020","unstructured":"Fitzgerald KA, Kagan JC (2020) Toll-like receptors and the control of immunity. Cell 180:1044\u20131066. https:\/\/doi.org\/10.1016\/j.cell.2020.02.041","journal-title":"Cell"},{"key":"12688_CR34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher AM, Workman CJ, Vignali DAA (2022) Interferon-gamma: teammate or opponent in the tumour microenvironment? Nat Rev Immunol 22:158\u2013172. https:\/\/doi.org\/10.1038\/s41577-021-00566-3","journal-title":"Nat Rev Immunol"},{"key":"12688_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2022.100122","volume":"14","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang Y, Fu Y (2022) The critical role of Toll-like receptor-mediated signaling in cancer immunotherapy. Med Drug Discov 14:100122","journal-title":"Med Drug Discov"},{"key":"12688_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10565-012-9221-2","volume":"28","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Wang Y, Yuan J, Qin W, Liu F, Wang F, Zhang G, Yang X (2012) Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells. Cell Biol Toxicol 28:269\u2013277. https:\/\/doi.org\/10.1007\/s10565-012-9221-2","journal-title":"Cell Biol Toxicol"},{"key":"12688_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/dote.12466","volume":"30","author":"Y Zu","year":"2017","unstructured":"Zu Y, Ping W, Deng T, Zhang N, Fu X, Sun W (2017) Lipopolysaccharide-induced toll-like receptor 4 signaling in esophageal squamous cell carcinoma promotes tumor proliferation and regulates inflammatory cytokines expression. Dis Esophagus 30:1\u20138. https:\/\/doi.org\/10.1111\/dote.12466","journal-title":"Dis Esophagus"},{"key":"12688_CR38","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1186\/1471-2407-10-665","volume":"10","author":"S Gonz\u00e1lez-Reyes","year":"2010","unstructured":"Gonz\u00e1lez-Reyes S, Mar\u00edn L, Gonz\u00e1lez L, Gonz\u00e1lez LO, del Casar JM, Lamelas ML, Gonz\u00e1lez-Quintana JM, Vizoso F (2010) Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 10:665","journal-title":"BMC Cancer"},{"issue":"2830\u20132846","key":"12688_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.08.015","volume":"58","author":"G Mattavelli","year":"2025","unstructured":"Mattavelli G, Helal M, Cetkovic A, Kramer MJ, Herbert SL, Mielert K, Schlaiss T, Frank A, Riemer E, John M, Martinez Vasquez JDP, Kindl L, Swietlik JJ, Gansen BO, Krafft M, Stanojkovska E, Fischer H, Albert US, Bauer J, Delgobo M, Aintablian A, Alattar H, Lutz MB, Meissner F, Oskarsson T, Rasche L, Ramos G, Rosenwald A, Wockel A, Riedel A (2025) A TLR4-dependent fibroblast-monocyte axis in tumor-draining lymph nodes contributes to metastasis in triple-negative breast cancer. Immunity 58(2830\u20132846):e15. https:\/\/doi.org\/10.1016\/j.immuni.2025.08.015","journal-title":"Immunity"},{"key":"12688_CR40","first-page":"7034","volume":"8","author":"X Chen","year":"2015","unstructured":"Chen X, Zhao F, Zhang H, Zhu Y, Wu K, Tan G (2015) Significance of TLR4\/MyD88 expression in breast cancer. Int J Clin Exp Pathol 8:7034\u20137039","journal-title":"Int J Clin Exp Pathol"},{"key":"12688_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1336696","volume":"14","author":"H Zheng","year":"2024","unstructured":"Zheng H, Wu X, Guo L, Liu J (2024) MyD88 signaling pathways: role in breast cancer. Front Oncol 14:1336696. https:\/\/doi.org\/10.3389\/fonc.2024.1336696","journal-title":"Front Oncol"},{"key":"12688_CR42","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/ncb3058","volume":"16","author":"FA Scheeren","year":"2014","unstructured":"Scheeren FA, Kuo AH, Van Weele LJ, Cai S, Glykofridis I, Sikandar SS, Zabala M, Qian D, Lam JS, Johnston D (2014) A cell-intrinsic role for TLR2\u2013MYD88 in intestinal and breast epithelia and oncogenesis. Nat Cell Biol 16:1238\u20131248","journal-title":"Nat Cell Biol"},{"key":"12688_CR43","doi-asserted-by":"publisher","first-page":"6017","DOI":"10.1007\/s13277-015-4436-5","volume":"37","author":"F Xiang","year":"2016","unstructured":"Xiang F, Ni Z, Zhan Y, Kong Q, Xu J, Jiang J, Wu R, Kang X (2016) Increased expression of MyD88 and association with paclitaxel resistance in breast cancer. Tumor Biol 37:6017\u20136025","journal-title":"Tumor Biol"},{"key":"12688_CR44","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1126\/science.1158298","volume":"321","author":"H von Bernuth","year":"2008","unstructured":"von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku CL, Chrabieh M, Mustapha IB, Ghandil P, Camcioglu Y, Vasconcelos J, Sirvent N, Guedes M, Vitor AB, Herrero-Mata MJ, Arostegui JI, Rodrigo C, Alsina L, Ruiz-Ortiz E, Juan M, Fortuny C, Yague J, Anton J, Pascal M, Chang HH, Janniere L, Rose Y, Garty BZ, Chapel H, Issekutz A, Marodi L, Rodriguez-Gallego C, Banchereau J, Abel L, Li X, Chaussabel D, Puel A, Casanova JL (2008) Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321:691\u2013696. https:\/\/doi.org\/10.1126\/science.1158298","journal-title":"Science"},{"key":"12688_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00501","volume":"9","author":"F Xiang","year":"2019","unstructured":"Xiang F, Fan Y, Ni Z, Liu Q, Zhu Z, Chen Z, Hao W, Yue H, Wu R, Kang X (2019) Ursolic acid reverses the chemoresistance of breast cancer cells to paclitaxel by targeting MiRNA-149-5p\/MyD88. Front Oncol 9:501. https:\/\/doi.org\/10.3389\/fonc.2019.00501","journal-title":"Front Oncol"},{"key":"12688_CR46","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2007.12.003","volume":"13","author":"Y H\u00fcsemann","year":"2008","unstructured":"H\u00fcsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethm\u00fcller G (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13:58\u201368","journal-title":"Cancer Cell"},{"key":"12688_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv364","volume":"108","author":"L Xie","year":"2016","unstructured":"Xie L, Jiang FC, Zhang LM, He WT, Liu JH, Li MQ, Zhang X, Xing S, Guo H, Zhou P (2016) Targeting of MyD88 homodimerization by novel synthetic inhibitor TJ-M2010-5 in preventing colitis-associated colorectal cancer. J Natl Cancer Inst 108:djv364. https:\/\/doi.org\/10.1093\/jnci\/djv364","journal-title":"J Natl Cancer Inst"},{"key":"12688_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/srep14246","volume":"5","author":"MA Olson","year":"2015","unstructured":"Olson MA, Lee MS, Kissner TL, Alam S, Waugh DS, Saikh KU (2015) Discovery of small molecule inhibitors of MyD88-dependent signaling pathways using a computational screen. Sci Rep 5:14246. https:\/\/doi.org\/10.1038\/srep14246","journal-title":"Sci Rep"},{"key":"12688_CR49","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.cellimm.2011.10.008","volume":"272","author":"AT Egunsola","year":"2012","unstructured":"Egunsola AT, Zawislak CL, Akuffo AA, Chalmers SA, Ewer JC, Vail CM, Lombardo JC, Perez DN, Kurt RA (2012) Growth, metastasis, and expression of CCL2 and CCL5 by murine mammary carcinomas are dependent upon Myd88. Cell Immunol 272:220\u2013229","journal-title":"Cell Immunol"},{"key":"12688_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01780","volume":"10","author":"A Singh","year":"2020","unstructured":"Singh A, Devkar R, Basu A (2020) Myeloid differentiation primary response 88\u2013cyclin D1 signaling in breast cancer cells regulates toll-like receptor 3-mediated cell proliferation. Front Oncol 10:1780","journal-title":"Front Oncol"},{"key":"12688_CR51","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s12672-025-02471-w","volume":"16","author":"N Hedayati","year":"2025","unstructured":"Hedayati N, Safari MH, Milasi YE, Kahkesh S, Farahani N, Khoshnazar SM, Dorostgou Z, Alaei E, Alimohammadi M, Rahimzadeh P, Taheriazam A, Hashemi M (2025) Modulation of the PI3K\/Akt signaling pathway by resveratrol in cancer: molecular mechanisms and therapeutic opportunity. Discov Oncol 16:669. https:\/\/doi.org\/10.1007\/s12672-025-02471-w","journal-title":"Discov Oncol"},{"key":"12688_CR52","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","volume":"186","author":"E Nolan","year":"2023","unstructured":"Nolan E, Lindeman GJ, Visvader JE (2023) Deciphering breast cancer: from biology to the clinic. Cell 186:1708\u20131728. https:\/\/doi.org\/10.1016\/j.cell.2023.01.040","journal-title":"Cell"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12688-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12688-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12688-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:03:25Z","timestamp":1789117405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12688-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12688"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12688-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"3 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from participants for the publication.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that all participants provided informed consent prior to the study.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted in accordance with the guidelines of the Declaration of Helsinki. The Ethical Committee of Mansoura University gave approval (Institutional Review Board [IRB] (code: MDP.24.09.165).","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1561"}}